trapidil has been researched along with Arteriosclerosis Obliterans in 2 studies
Trapidil: A coronary vasodilator agent.
Arteriosclerosis Obliterans: Common occlusive arterial disease which is caused by ATHEROSCLEROSIS. It is characterized by lesions in the innermost layer (ARTERIAL INTIMA) of arteries including the AORTA and its branches to the extremities. Risk factors include smoking, HYPERLIPIDEMIA, and HYPERTENSION.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Regenthal, R | 1 |
| Voigt, H | 2 |
| Reuter, W | 2 |
| Preiss, R | 1 |
| Hofmann, B | 1 |
| Dobberkau, A | 1 |
2 trials available for trapidil and Arteriosclerosis Obliterans
| Article | Year |
|---|---|
[The effect of oral trapidil therapy on clinical and hemorheological parameters in arteriosclerosis obliterans in comparison to pentoxifylline--a pilot study].
Topics: Adult; Arteriosclerosis Obliterans; Blood Viscosity; Fibrinogen; Humans; Intermittent Claudication; | 1991 |
[Oral trapidil treatment of Fontaine stage II arteriosclerotic circulatory disorders of the legs--a double-blind study].
Topics: Aged; Arteriosclerosis Obliterans; Cholesterol; Double-Blind Method; Female; Humans; Ischemia; Leg; | 1990 |